NYSE:TMBR Timber Pharmaceuticals (TMBR) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free TMBR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.34▼$2.9452-Week Range N/AVolume26,307 shsAverage Volume511,937 shsMarket Capitalization$1.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesSocial Media Get Timber Pharmaceuticals alerts: Email Address Ad InvestorPlaceElon Musk’s Controversial New Project: “Apollo”Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...Click here to see the details because there's a lot of money at stake. About Timber Pharmaceuticals Stock (NYSE:TMBR)Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey.Read More Ad InvestorPlaceElon Musk’s Controversial New Project: “Apollo”Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...Click here to see the details because there's a lot of money at stake. TMBR Stock News HeadlinesMarch 10, 2024 | businesswire.comTimber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual MeetingJanuary 28, 2024 | msn.comTimber Pharmaceuticals Announces Official Name ChangeApril 24, 2024 | InvestorPlace (Ad)Elon Musk’s Controversial New Project: “Apollo”Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...January 13, 2024 | uk.investing.comTimber Pharmaceuticals Inc (TMBRQ)November 29, 2023 | finance.yahoo.comTimber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC MarketNovember 29, 2023 | finance.yahoo.comNYSE American to Suspend Trading Immediately in Timber Pharmaceuticals, Inc. (TMBR)November 28, 2023 | tmcnet.comTimber Pharmaceuticals Receives Court Approval of All "First Day" Motions to Support Business Operations & Discloses Communication From NYSE AmericanNovember 28, 2023 | finance.yahoo.comTimber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE AmericanApril 24, 2024 | InvestorPlace (Ad)Elon Musk’s Controversial New Project: “Apollo”Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...November 21, 2023 | seekingalpha.comMVST, FBIO and VTVT among mid-day moversNovember 17, 2023 | msn.comTimber Pharmaceuticals files for Chapter 11 in wake of failed mergerNovember 16, 2023 | msn.comTimber Pharma slips ahead of shareholder vote on mergerSeptember 18, 2023 | finance.yahoo.comTimber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing ComplianceAugust 29, 2023 | 247wallst.comHC Wainwright Downgrades Timber PharmaceuticalsAugust 28, 2023 | msn.comHC Wainwright & Co. Downgrades Timber Pharmaceuticals (TMBR)August 21, 2023 | benzinga.comTMBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Timber Pharmaceuticals, Inc. Is Fair to ShareholdersAugust 21, 2023 | markets.businessinsider.comDow Tumbles Over 100 Points; Timber Pharmaceuticals Shares Spike HigherAugust 21, 2023 | msn.comTimber to be taken private by LEO Pharma, stock soars 100%August 21, 2023 | investorplace.comWhy Is Timber Pharmaceuticals (TMBR) Stock Up 96% Today?August 21, 2023 | markets.businessinsider.comUS Stocks Mostly Higher; Nasdaq Jumps 100 PointsAugust 21, 2023 | marketwatch.comTimber Pharmaceuticals Shares Soar on Takeover by LEO PharmaAugust 21, 2023 | benzinga.comWhy Timber Pharmaceuticals Stock Is Skyrocketing TodayAugust 21, 2023 | finance.yahoo.comLEO Pharma Signs Agreement to Acquire Timber PharmaceuticalsAugust 21, 2023 | finance.yahoo.comTimber Pharmaceuticals to be Acquired by LEO PharmaAugust 15, 2023 | morningstar.comTimber Pharmaceuticals Inc Ordinary SharesJuly 3, 2023 | finance.yahoo.comTimber Pharmaceuticals Discloses Communication From NYSE AmericanJune 5, 2023 | msn.comTimber Pharmaceuticals Soars as FDA Removes HurdleSee More Headlines Receive TMBR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Timber Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:TMBR CUSIPN/A CIK1504167 Webwww.timberpharma.com Phone(973) 314-9577FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,380,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-511.45% Return on Assets-180.93% Debt Debt-to-Equity RatioN/A Current Ratio0.50 Quick Ratio0.50 Sales & Book Value Annual Sales$80,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.79 per share Price / BookN/AMiscellaneous Outstanding Shares3,430,000Free Float3,378,000Market Cap$1.21 million OptionableNot Optionable Beta0.03 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. John Koconis M.B.A. (Age 53)Chairman, CEO & President Comp: $570.19kMr. Joseph Lucchese (Age 56)Executive VP, CFO, Treasurer & Secretary Comp: $542.3kDr. Alan Mendelsohn M.D. (Age 60)Executive VP & Chief Medical Officer Comp: $507.16kKey CompetitorsSunshine BiopharmaNASDAQ:SBFMComera Life SciencesNASDAQ:CMRABiodexa PharmaceuticalsNASDAQ:BDRXGRI BioNASDAQ:GRIPanbela TherapeuticsNASDAQ:PBLAView All Competitors TMBR Stock Analysis - Frequently Asked Questions Should I buy or sell Timber Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Timber Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" TMBR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TMBR, but not buy additional shares or sell existing shares. View TMBR analyst ratings or view top-rated stocks. When did Timber Pharmaceuticals' stock split? Shares of Timber Pharmaceuticals reverse split on the morning of Wednesday, November 9th 2022. The 1-50 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. This page (NYSE:TMBR) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Timber Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.